OM
Opaleye Management Portfolio holdings
AUM
$494M
This Quarter Return
+25.06%
1 Year Return
+68.17%
3 Year Return
+608.37%
5 Year Return
+807.76%
10 Year Return
+24,567.29%
AUM
$288M
AUM Growth
+$288M
(+19%)
Cap. Flow
+$14.9M
Cap. Flow
% of AUM
5.18%
Top 10 Holdings %
Top 10 Hldgs %
61.77%
Holding
53
New
11
Increased
10
Reduced
18
Closed
13
Top Buys
| 1 |
Biohaven
BHVN
|
$7.5M |
| 2 |
Harrow
HROW
|
$6.36M |
| 3 |
KalVista Pharmaceuticals
KALV
|
$6.24M |
| 4 |
Phathom Pharmaceuticals
PHAT
|
$4.68M |
| 5 |
Karyopharm Therapeutics
KPTI
|
$4.28M |
Top Sells
| 1 |
CUTR
Cutera, Inc.
CUTR
|
$6.74M |
| 2 |
ProQR Therapeutics
PRQR
|
$6.12M |
| 3 |
INBX
Inhibrx, Inc. Common Stock
INBX
|
$5.25M |
| 4 |
Merus
MRUS
|
$5.07M |
| 5 |
Keros Therapeutics
KROS
|
$4M |
Sector Composition
| 1 | Healthcare | 98.86% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Harrow
HROW
$1.44B
| $55.7M | 19.38% | 3,775,000 +431,183 | +13% | +$6.36M |
|
2
TELA Bio
TELA
$70.5M
| $23.8M | 8.29% | 2,072,813 +36,262 | +2% | +$417K |
|
3
Rhythm Pharmaceuticals
RYTM
$6.85B
| $21.4M | 7.44% | 735,000 -75,000 | -9% | -$2.18M |
|
4
Ocular Therapeutix
OCUL
$2.12B
| $17.1M | 5.94% | 6,075,000 -390,000 | -6% | -$1.1M |
|
5
Crinetics Pharmaceuticals
CRNX
$2.92B
| $13.4M | 4.66% | 732,000 +60,700 | +9% | +$1.11M |
|
6
Cytokinetics
CYTK
$4.23B
| $11.5M | 3.98% | 250,000 -13,000 | -5% | -$596K |
|
|
7
Keros Therapeutics
KROS
$618M
| $11.4M | 3.97% | 238,000 -83,300 | -26% | -$4M |
|
8
Vaxcyte
PCVX
$4B
| $8.49M | 2.95% | 177,000 -13,000 | -7% | -$623K |
|
|
9
Biohaven
BHVN
$1.63B
| $7.5M | 2.61% | +540,000 | New | +$7.5M |
|
10
4D Molecular Therapeutics
FDMT
$288M
| $7.33M | 2.55% | 330,000 -20,700 | -6% | -$460K |
|
11
Protara Therapeutics
TARA
$120M
| $7.22M | 2.51% | 2,692,594 -15,473 | -0.6% | -$41.5K |
|
|
TCON
12
DELISTED
TRACON Pharmaceuticals, Inc. Common Stock
TCON
| $6.84M | 2.38% | 4,590,000 +400,000 | +10% | +$596K |
|
13
Larimar Therapeutics
LRMR
$310M
| $6.44M | 2.24% | 1,560,000 -101,784 | -6% | -$420K |
|
|
14
KalVista Pharmaceuticals
KALV
$678M
| $6.24M | 2.17% | +923,200 | New | +$6.24M |
|
15
Eton Pharmaceutcials
ETON
$464M
| $6.12M | 2.13% | 2,170,000 -351,000 | -14% | -$990K |
|
16
Edgewise Therapeutics
EWTX
$1.51B
| $5.47M | 1.9% | 611,400 -23,600 | -4% | -$211K |
|
|
17
ProQR Therapeutics
PRQR
$237M
| $5.4M | 1.88% | 1,460,000 -1,655,000 | -53% | -$6.12M |
|
|
18
Phathom Pharmaceuticals
PHAT
$864M
| $4.68M | 1.63% | +417,500 | New | +$4.68M |
|
19
Xoma
XOMA
$392M
| $4.47M | 1.55% | 243,000 -5,000 | -2% | -$92K |
|
20
Codexis
CDXS
$246M
| $4.46M | 1.55% | 957,500 -197,500 | -17% | -$920K |
|
21
UroGen Pharma
URGN
$900M
| $4.33M | 1.51% | 488,656 +91,156 | +23% | +$809K |
|
|
22
Karyopharm Therapeutics
KPTI
$61.7M
| $4.28M | 1.49% | +1,206,841 | New | +$4.28M |
|
23
Astria Therapeutics
ATXS
$349M
| $3.9M | 1.36% | 261,703 +128,203 | +96% | +$1.91M |
|
24
Liquidia Corp
LQDA
$2.38B
| $3.57M | 1.24% | 560,000 -3,500 | -0.6% | -$22.3K |
|
25
Zentalis Pharmaceuticals
ZNTL
$122M
| $3.37M | 1.17% | +167,500 | New | +$3.37M |
|